Aclaris Therapeutics, Inc. (ACRS) vs Crescent Biopharma, Inc. (CBIO)
A side-by-side comparison of Aclaris Therapeutics, Inc. and Crescent Biopharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ACRS
Aclaris Therapeutics, Inc.
$3.94HealthcareDelayed quote: Oct 6, 2026, 12:15 PM EDT
CBIO
Crescent Biopharma, Inc.
$14.08HealthcareDelayed quote: Oct 6, 2026, 12:15 PM EDT
Total return — ACRS vs CBIO
growth of $100 · dividends reinvested · last 10yACRS -83.0% (-16.2%/yr)CBIO -92.7% (-23.0%/yr)ACRS compounded faster over this window
ACRS CBIO
ACRS vs CBIO: by the numbers
- •ACRS is the larger company ($550M vs $523M market cap).
- •Both run net losses; ACRS's is the smaller (-921.50% vs -1371.51% net margin).
- •CBIO grew revenue faster over the past five years (39.89% vs 4.39% CAGR).
Metrics side by side
Valuation
| Metric | ACRS | CBIO |
|---|---|---|
| P/S ratio | 66.93 | 44.01 |
| P/B ratio | 4.42 | 3.28 |
Profitability
| Metric | ACRS | CBIO |
|---|---|---|
| Gross margin | 73.28% | 100.00% |
| Operating margin | -975.91% | -1407.52% |
| Net margin | -921.50% | -1371.51% |
| ROE | -60.79% | -99.83% |
| ROIC | -56.99% | -102.59% |
Growth (annualized)
| Metric | ACRS | CBIO |
|---|---|---|
| Revenue CAGR (5Y) | 4.39% | 39.89% |
| Total return CAGR (5Y) | -24.23% | -24.40% |
Frequently asked
- Which has grown faster, ACRS or CBIO?
- Over the past five years, CBIO grew revenue faster — ACRS at a 4.39% CAGR versus CBIO at 39.89%.
- How have ACRS and CBIO total returns compared?
- Over the past 10 years, ACRS delivered -16.23% and CBIO delivered -22.94% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Aclaris Therapeutics ROECrescent Biopharma ROEAclaris Therapeutics operating marginCrescent Biopharma operating marginAclaris Therapeutics revenue growthCrescent Biopharma revenue growthAclaris Therapeutics free cash flowCrescent Biopharma free cash flow
Aclaris Therapeutics & Crescent Biopharma appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.